Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?

Anixa Biosciences (ANIX) is outperforming its medical sector peers, with a year-to-date return of 20.3% compared to the sector's average loss of 4.4%, driven by a 7.3% increase in its full-year earnings consensus estimate and a Zacks Rank of #2 (Buy). Similarly, Cellectar Biosciences (CLRB) has delivered a 54.4% year-to-date return, supported by a 12.1% increase in its current year EPS estimate and also holds a Zacks Rank #2 (Buy).

Analysis

Anixa Biosciences (ANIX) has demonstrated significant outperformance year-to-date, with its stock appreciating approximately 20.3%, in stark contrast to the Medical group's average loss of 4.4% and the Medical - Biomedical and Genetics industry's average loss of 4%. This positive momentum is underpinned by a Zacks Rank of #2 (Buy) and a 7.3% upward revision in its full-year earnings consensus estimate over the past quarter, signaling strengthening analyst sentiment and an improving earnings outlook. Similarly, Cellectar Biosciences (CLRB), another entity within the broader Medical sector, has exhibited even stronger performance, returning 54.4% year-to-date. CLRB also holds a Zacks Rank #2 (Buy), supported by a 12.1% increase in its consensus EPS estimate for the current year over the past three months. While ANIX belongs to the Medical - Biomedical and Genetics industry (Zacks Industry Rank #78), CLRB is part of the Medical - Products industry (Zacks Industry Rank #134), which itself has seen a positive year-to-date move of 5.2%. The Zacks Rank system, which emphasizes earnings estimates and revisions, suggests both companies possess characteristics indicative of potential market outperformance in the near term.

Key Decisions for Investors

• Investors seeking exposure to outperforming stocks within the Medical sector may find Anixa Biosciences (ANIX) an attractive option, given its 20.3% year-to-date return, positive earnings estimate revisions of 7.3%, and a Zacks Rank #2 (Buy).
• Cellectar Biosciences (CLRB) also warrants consideration due to its substantial 54.4% year-to-date gain, a 12.1% increase in its current year EPS estimate, and a favorable Zacks Rank #2 (Buy), positioning it as a strong performer in the Medical - Products industry.
• Monitor ongoing changes in Zacks Ranks and consensus earnings estimates for both ANIX and CLRB, as these are highlighted as key drivers of their recent positive performance and future outlook.
• Despite the individual strength of these companies, be mindful of the broader Medical sector's -4.4% average year-to-date decline and the Medical - Biomedical and Genetics industry's -4% trend when assessing overall portfolio risk and allocation.